# EDGAR Filing Document

**Accession Number:** 0001399708
**File Stem:** 0001104659-23-029122
**Filing Date:** 2023-3
**Character Count:** 16945
**Document Hash:** c23afcba472f7a98d0d7c88dd1ba105a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-029122.hdr.sgml**: 20230307

**ACCESSION NUMBER**: 0001104659-23-029122

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 4

**CONFORMED PERIOD OF REPORT**: 20230306

**FILED AS OF DATE**: 20230307

**DATE AS OF CHANGE**: 20230306

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NEOVASC INC
- **CENTRAL INDEX KEY:** 0001399708
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36458
- **FILM NUMBER:** 23710195

**BUSINESS ADDRESS:**
- **STREET 1:** 2135 13700 Mayfield place
- **CITY:** RICHMOND
- **STATE:** A1
- **ZIP:** 00000
- **BUSINESS PHONE:** 604-270-4344

**MAIL ADDRESS:**
- **STREET 1:** 2135 13700 Mayfield place
- **CITY:** RICHMOND
- **STATE:** A1
- **ZIP:** 00000

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Medical Ventures Corp
- **DATE OF NAME CHANGE:** 20070516

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16<br> OF THE SECURITIES EXCHANGE ACT OF 1934**

For the Month of **March 2023**

Commission File Number: **001-36458**

**<u>NEOVASC INC.</u>**

(Translation of registrant's name in English)

**Suite 5138 - 13562 Maycrest Way**

**Richmond, British Columbia, Canada, V6V 2J7**

(Address of principal executive offices and zip code)

Indicate by check mark whether the Registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

⌧ Form 20-F ◻ Form 40-F

**<u>SIGNATURES</u>**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **NEOVASC INC.** | **NEOVASC INC.** |
|  | By: | */s/ Chris Clark* |
|  |  | Chris Clark, Chief Financial Officer |
| Date: March 6, 2023 |  |  |

---

---

| | |
|:---|:---|
|  | **EXHIBIT LIST** |
| **Exhibit No.** | **Description** |
| [99.1](tm238538d1_ex99-1.htm) | [Press Release](tm238538d1_ex99-1.htm) |
| [99.2](tm238538d1_ex99-2.htm) | [Report of Voting Results](tm238538d1_ex99-2.htm) |

---

## Exhibit 99.1

**Exhibit 99.1**

![](tm238538d1_ex99-1img001.jpg)

**Neovasc Shareholders Approve Acquisition by Shockwave Medical**

**VANCOUVER** **, BC – March 6, 2023 –** Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive devices for the treatment of refractory angina, is pleased to announce that its Shareholders (as defined below) have approved the previously-announced acquisition of all of the outstanding common shares of the Company (the "Shares") by Shockwave Medical, Inc. ("Shockwave") by way of a statutory plan of arrangement (the "Arrangement") at the special meeting of Shareholders held today (the "Meeting").

The special resolution approving the Arrangement was approved by: (i) 97.36% of the votes cast by the shareholders of the Company (the "Shareholders") present in person or represented by proxy at the Meeting, and (ii) 97.21% of the votes cast by Shareholders, other than those Shareholders required to be excluded pursuant to Multilateral Instrument 61-101 – *Protection of Minority Security Holders in Special Transactions*, present in person or represented by proxy at the Meeting.

The Arrangement remains subject to the approval of the Supreme Court of British Columbia (the "Court") and the satisfaction or waiver of other customary closing conditions. The Court hearing for the final order to approve the Arrangement is scheduled to take place on March 9, 2023, and the completion of the Arrangement is expected to occur in March 2023, on a date to be determined. Until the closing of the Arrangement, the parties remain separate independent companies. Following completion of the Arrangement, the Shares will be delisted from the Toronto Stock Exchange (the "TSX") and the Nasdaq Capital Market (the "Nasdaq"). An application will also be made for the Company to cease to be a reporting issuer in the applicable jurisdictions following completion of the Arrangement. The Company will also deregister the Shares under the U.S. Securities Exchange Act of 1934, as amended.

Further details regarding the Arrangement are set out in the Company's management information circular dated February 3, 2023 which is available on Neovasc's profile at www.sedar.com.

**ABOUT NEOVASC**

Neovasc is a specialty medical device company that develops, manufactures, and markets products for the rapidly growing cardiovascular marketplace. Its products include Neovasc Reducer™, for the treatment of refractory angina, which is under clinical investigation in the United States and has been commercially available in Europe since 2015, and Tiara™, for the transcatheter treatment of mitral valve disease, which is under clinical investigation in the United States, Canada, Israel, and Europe and for which activity has been indefinitely paused. The Company remains committed to the ongoing follow-up of patients in Tiara clinical trials and has paused all other Tiara activities. For more information, visit: www.neovasc.com.

**FORWARD-LOOKING STATEMENT DISCLAIMER**

Certain statements in this news release contain forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws that may not be based on historical fact. When used herein, the words "expect", "anticipate", "estimate", "may", "will", "should", "intend", "believe", and similar expressions, are intended to identify forward-looking statements. Forward-looking statements may involve, but are not limited to, the proposed timing and completion of the Arrangement; the satisfaction of the conditions precedent to the Arrangement; timing, receipt and anticipated effects of Court and other consents and approvals. Forward-looking statements are based on estimates and assumptions made by the Company in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors that the Company believes are appropriate in the circumstances. Many factors and assumptions could cause the Company's actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements, including, without limitation, risks that a condition to closing of the Arrangement may not be satisfied; risks that Court or other applicable approvals for the Arrangement may not be obtained or be obtained subject to conditions that are not anticipated; risks around the Company's ability to continue as a going concern; risks around the Company's history of losses and significant accumulated deficit; risks related to the COVID-19 coronavirus outbreak or other health epidemics, which could significantly impact the Company's operations, sales or ability to raise capital or enroll patients in clinical trials; risks relating to the Company's need for significant additional future capital and the Company's ability to raise additional funding; risks relating to the sale of a significant number of Shares; risks relating to the possibility that the Company's Shares may be delisted from the Nasdaq or the TSX, which could affect their market price and liquidity; risks relating to the Company's conclusion that it did have effective internal control over financial reporting as of December 31, 2021 and 2020 but not at December 31, 2019; risks relating to the Share price being volatile; risks relating to the Company's significant indebtedness and its effect on the Company's financial condition; risks relating to the influence of significant shareholders of the Company over our business operations and share price; risks relating to lawsuits that the Company is subject to, which could divert the Company's resources and result in the payment of significant damages and other remedies; risks relating to claims by third-parties alleging infringement of their intellectual property rights; risks relating to the Company's ability to establish, maintain and defend intellectual property rights in the Company's products; risks relating to results from clinical trials of the Company's products, which may be unfavorable or perceived as unfavorable; risks associated with product liability claims, insurance and recalls; risks relating to use of the Company's products in unapproved circumstances, which could expose the Company to liabilities; risks relating to competition in the medical device industry, including the risk that one or more competitors may develop more effective or more affordable products; risks relating to the Company's ability to achieve or maintain expected levels of market acceptance for the Company's products, as well as the Company's ability to successfully build its in-house sales capabilities or secure third-party marketing or distribution partners; risks relating to the Company's ability to convince public payors and hospitals to include the Company's products on their approved products lists; risks relating to new legislation, new regulatory requirements and the efforts of governmental and third-party payors to contain or reduce the costs of healthcare; risks relating to increased regulation, enforcement and inspections of participants in the medical device industry, including frequent government investigations into marketing and other business practices; risks relating to the extensive regulation of the Company's products and trials by governmental authorities, as well as the cost and time delays associated therewith; risks relating to post-market regulation of the Company's products; risks relating to health and safety concerns associated with the Company's products and industry; risks relating to the Company's manufacturing operations, including the regulation of the Company's manufacturing processes by governmental authorities and the availability of two critical components of the Reducer; risks relating to the possibility of animal disease associated with the use of the Company's products; risks relating to the manufacturing capacity of third-party manufacturers for the Company's products, including risks of supply interruptions impacting the Company's ability to manufacture its own products; risks relating to the Company's dependence on limited products for substantially all of the Company's current revenues; risks relating to the Company's exposure to adverse movements in foreign currency exchange rates; risks relating to the possibility that the Company could lose its foreign private issuer status under U.S. federal securities laws; risks relating to the possibility that the Company could be treated as a "passive foreign investment company"; risks relating to breaches of anti-bribery laws by the Company's employees or agents; risks relating to future changes in financial accounting standards and new accounting pronouncements; risks relating to the Company's dependence upon key personnel to achieve its business objectives; risks relating to the Company's ability to maintain strong relationships with physicians; risks relating to the sufficiency of the Company's management systems and resources in periods of significant growth; risks relating to consolidation in the health care industry, including the downward pressure on product pricing and the growing need to be selected by larger customers in order to make sales to their members or participants; risks relating to the Company's ability to successfully identify and complete corporate transactions on favorable terms or achieve anticipated synergies relating to any acquisitions or alliances; risks relating to conflicts of interests among the Company's officers and directors as a result of their involvement with other issuers; risks relating to future issuances of equity securities by the Company, or sales of Shares or conversions of convertible notes, and exercise of warrants, options and restricted stock units by existing security holders, causing the price of the Company's securities to fall; and risks relating to anti-takeover provisions in the Company's constating documents which could discourage a third-party from making a takeover bid beneficial to the Company's shareholders. These risk factors and others relating to the Company are discussed in greater detail in the "Risk Factors" section of the Company's Annual Report on Form 20-F for the year ended December 31, 2021 and in the Management's Discussion and Analysis for the three and nine months ended September 30, 2022 (copies of which may be obtained at www.sedar.com or www.sec.gov). These factors should be considered carefully, and readers should not place undue reliance on the Company's forward-looking statements. The Company has no intention and undertakes no obligation to update or revise any forward-looking statements beyond required periodic filings with securities regulators (copies of which may be obtained at www.sedar.com or www.sec.gov), whether because of new information, future events or otherwise, except as required by law.

**Contacts**

*Investors:*

Mike Cavanaugh

ICR Westwicke

Phone: +1.617.877.9641

Email: Mike.Cavanaugh@westwicke.com

*Media:*

Sean Leous

ICR Westwicke

Phone: +1.646.866.4012

Email: Sean.Leous@westwicke.com

## Exhibit 99.2

**Exhibit 99.2**

**Special Meeting of Shareholders of**

**Neovasc Inc. (the "Company")**

**March 6, 2023**

**REPORT OF VOTING RESULTS**

**Pursuant to Section 11.3 of National Instrument 51-102**

This report sets out the matter voted upon and the results of the votes conducted at the special meeting (the "**Meeting**") of holders of common shares (the "**Shares**") of the Company held on March 6, 2023.

The total number of Shares voting in person or represented by proxy at the Meeting was 1,049,083 Shares, representing approximately 38.02% of the Company's issued and outstanding Shares, as of the record date of February 3, 2023.

**Approval of Arrangement Resolution**

At the Meeting, the holders of the Shares (the "**Shareholders**") approved a special resolution, the full text of which is set forth in Appendix B to the management information circular of the Company dated February 3, 2023 (the "**Circular**"), to approve a plan of arrangement (the "**Arrangement**") under section 192 of the *Canada Business Corporations Act* involving the Company and Shockwave Medical, Inc. (the "**Purchaser**"). Pursuant to the Arrangement, the Purchaser will, among other things, acquire all of the outstanding Shares for a cash consideration of US$27.25 per Share for an initial aggregate consideration of approximately US$100 million, plus potential deferred payments of up to approximately US$47 million on the achievement of future regulatory milestones in the form of a contingent value right ("**CVR**") per Share to receive payment upon final FDA premarket approval to market the Neovasc Reducer<sup>TM</sup> in the United States for treatment of angina (the "**Milestone**"). Each CVR has the potential to pay, as applicable and without any aggregation, an amount equal to: (i) US$12.00 if the Milestone is achieved on or prior to June 30, 2026, (ii) US$8.00 if the Milestone is achieved during the period beginning on July 1, 2026 and ending on December 31, 2026 or (iii) US$4.00 if the Milestone is achieved during the period beginning on January 1, 2027 and ending on December 31, 2027.

Full details of the special resolution and the Arrangement are set out in the Circular, available under the Company's SEDAR profile at <u>www.sedar.com</u>.

The following is a summary of the votes cast by ballot by Shareholders:

---

| | | |
|:---|:---|:---|
|  | &nbsp;&nbsp;**Total Votes** | &nbsp;&nbsp;**Voted (%)** |
| Votes For | &nbsp;&nbsp;1021439 | &nbsp;&nbsp;97.36 |
| Votes Against | &nbsp;&nbsp;27644 | &nbsp;&nbsp;2.64 |

---

The following is a summary of the votes cast by ballot by Shareholders, other than those Shareholders required to be excluded pursuant to Multilateral Instrument 61-101 – *Protection of Minority Security Holders in Special Transactions*:

---

| | | |
|:---|:---|:---|
|  | &nbsp;&nbsp;**Total Votes** | &nbsp;&nbsp;**Voted (%)** |
| Votes For | &nbsp;&nbsp;964291 | &nbsp;&nbsp;97.21 |
| Votes Against | &nbsp;&nbsp;27644 | &nbsp;&nbsp;2.79 |

---

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**DATED** this 6<sup>th</sup> day of March, 2023. | | |
|  | **NEOVASC INC.** | **NEOVASC INC.** |
|  | Per: |  |
|  |  | (signed) *"Chris Clark"* |
|  |  | Chris Clark |
|  |  | Chief Financial Officer |

---

*Neovasc Inc. – Signature Page to Report of Voting Results*